Alkermes plc (ALKS) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Alkermes plc (ALKS) Healthcare & Pipeline Overview

Alkermes plc is a biopharmaceutical company specializing in central nervous system (CNS) disorders, leveraging proprietary technologies to develop and commercialize treatments for schizophrenia, bipolar disorder, and multiple sclerosis, while also collaborating with pharmaceutical partners to expand its market reach and address unmet medical needs.

What Is the Investment Thesis for ALKS?

With a market capitalization of $7.74B and a profit margin of 9.8%, the company demonstrates financial stability and growth potential. Key value drivers include the continued commercial success of ARISTADA and VIVITROL, as well as the potential approval and launch of LYBALVI. Growth catalysts include the expansion of nemvaleukin alfa into new oncology indications and strategic collaborations to broaden market reach. Potential risks include regulatory hurdles, competition from existing and emerging therapies, and the inherent uncertainties associated with drug development. The company's gross margin of 85.8% highlights its ability to maintain profitability, while its beta of 0.49 suggests lower volatility compared to the broader market.

Based on FMP financials and quantitative analysis

ALKS Key Highlights

Market capitalization of $7.74B reflects Alkermes' established position in the biopharmaceutical industry.

• Gross margin of 85.8% indicates efficient cost management and strong pricing power.
• Profit margin of 9.8% demonstrates the company's ability to generate profits from its operations.
• P/E ratio of 114.42 suggests a reasonable valuation relative to earnings.
• Beta of 0.49 indicates lower volatility compared to the overall market, potentially offering a more stable investment.

Who Are ALKS's Competitors?

ALKS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ALKS's Key Strengths?

Established portfolio of marketed products.

• Strong partnerships with major pharmaceutical companies.
• Innovative drug delivery technologies.
• Expertise in CNS drug development.

What Are ALKS's Weaknesses?

Reliance on a limited number of key products.

• Exposure to regulatory risks and patent challenges.
• High research and development costs.
• Competition from other biopharmaceutical companies.

What Could Drive ALKS Stock Higher?

Potential FDA approval and launch of LYBALVI for schizophrenia and bipolar I disorder.

• Clinical trial results for nemvaleukin alfa in various oncology indications.
• Continued commercial expansion of ARISTADA and VIVITROL.
• Strategic collaborations to expand product portfolio and market reach.

What Are the Key Risks for ALKS?

Rich valuation — a P/E of 114.42 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.

• Regulatory setbacks or delays in the approval of new drug candidates.
• Unfavorable clinical trial results for nemvaleukin alfa or other pipeline products.
• Competition from generic versions of existing products.
• Changes in healthcare regulations and reimbursement policies.
• Economic downturns and market volatility impacting pharmaceutical sales.

What Are the Growth Opportunities for ALKS?

• Expansion of LYBALVI: LYBALVI, an oral atypical antipsychotic drug candidate for schizophrenia and bipolar I disorder, represents a significant growth opportunity for Alkermes. The market for antipsychotic medications is substantial, with a global market size estimated at billions of dollars. If approved, LYBALVI could capture a significant share of this market, offering a new treatment option for patients with these conditions. The timeline for potential approval and launch is dependent on regulatory review and clinical trial outcomes, with potential for commercialization within the next 1-2 years.
• Development of Nemvaleukin Alfa: Nemvaleukin alfa, an engineered fusion protein designed to expand tumor-killing immune cells, holds promise as a novel cancer immunotherapy. Alkermes is exploring nemvaleukin alfa in various oncology indications, including melanoma and renal cell carcinoma. Positive clinical trial results could lead to regulatory approval and commercialization, potentially generating significant revenue streams for the company over the next 3-5 years.
• Geographic Expansion: Alkermes has the opportunity to expand its geographic presence beyond the United States and Ireland. The global market for CNS therapeutics is vast, with significant unmet needs in many regions. By entering new markets, Alkermes can increase its customer base and revenue streams. This expansion could involve establishing partnerships with local distributors or building its own commercial infrastructure in key international markets. The timeline for geographic expansion will depend on regulatory approvals and market access considerations in each target region.
• Strategic Collaborations: Alkermes can leverage strategic collaborations to expand its product portfolio and market reach. By partnering with other pharmaceutical companies, Alkermes can gain access to new technologies, drug candidates, and commercial expertise. These collaborations can take various forms, including licensing agreements, co-development partnerships, and joint ventures. Successful collaborations can accelerate the development and commercialization of new products, driving revenue growth and enhancing Alkermes' competitive position.
• Lifecycle Management of Existing Products: Alkermes can extend the lifecycle of its existing products through various strategies, such as developing new formulations, indications, and delivery methods. For example, Alkermes could explore new uses for ARISTADA or VIVITROL in different patient populations or in combination with other therapies. By continuously innovating and improving its existing products, Alkermes can maintain its market share and generate additional revenue streams. These efforts can provide ongoing revenue and market presence.

What Are ALKS's Competitive Advantages?

• Proprietary drug formulations and delivery technologies.
• Established partnerships with major pharmaceutical companies.
• Strong intellectual property protection for its products.
• Expertise in central nervous system (CNS) drug development.
• Established commercial infrastructure and distribution network.

What Does ALKS Do?

Founded in 1987 and headquartered in Dublin, Ireland, Alkermes plc is a biopharmaceutical company dedicated to researching, developing, and commercializing pharmaceutical products designed to address unmet medical needs across a range of therapeutic areas. The company's primary focus is on central nervous system (CNS) disorders, where it has established a portfolio of both proprietary and partnered products. Alkermes' marketed products include ARISTADA, an injectable medication for the treatment of schizophrenia; VIVITROL, used in the treatment of alcohol and opioid dependence; and VUMERITY, a treatment for relapsing forms of multiple sclerosis. Additionally, Alkermes has partnered with Janssen Pharmaceutica to commercialize RISPERDAL CONSTA, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, and TREVICTA, all used in the treatment of schizophrenia and schizoaffective disorder. The company is also actively developing LYBALVI, an oral antipsychotic drug candidate for schizophrenia and bipolar I disorder, and nemvaleukin alfa, an engineered fusion protein targeting tumor-killing immune cells. Alkermes operates in the United States, Ireland, and internationally, and its research and development efforts are geared towards creating innovative medicines that improve patient outcomes and address significant unmet needs in the CNS space.

What Products and Services Does ALKS Offer?

• Researches and develops pharmaceutical products.
• Commercializes pharmaceutical products.
• Focuses on addressing unmet medical needs in various therapeutic areas.
• Specializes in treatments for central nervous system (CNS) disorders.
• Markets ARISTADA for schizophrenia.
• Markets VIVITROL for alcohol and opioid dependence.
• Develops LYBALVI for schizophrenia and bipolar I disorder.
• Develops nemvaleukin alfa for cancer immunotherapy.

How Does ALKS Make Money?

• Develops and commercializes proprietary pharmaceutical products.
• Partners with other pharmaceutical companies to commercialize products.
• Generates revenue through product sales.
• Receives royalties and milestone payments from partnerships.

What Industry Does ALKS Operate In?

Alkermes plc operates within the biotechnology industry, a sector characterized by rapid innovation, intense competition, and high regulatory scrutiny. The market for CNS therapeutics is substantial, driven by the increasing prevalence of mental health disorders and neurological conditions. Alkermes competes with other biopharmaceutical companies, such as ARWR: Arrowhead Pharmaceuticals, Inc., PCVX: Vaxcyte, Inc., ACLX: Arcellx, Inc., PTGX: Protagonist Therapeutics, Inc., and TGTX: TG Therapeutics, Inc., all vying for market share in various therapeutic areas. The industry is also influenced by factors such as patent protection, clinical trial outcomes, and reimbursement policies.

Who Are ALKS's Key Customers?

• Patients with schizophrenia.
• Patients with alcohol dependence.
• Patients with opioid dependence.
• Patients with multiple sclerosis.
• Healthcare providers who prescribe Alkermes' medications.

Over the past six months, Alkermes plc insiders filed 84 SEC Form 4 transactions — 46 sales and 38 purchases. On net that is roughly 230K shares acquired (about $8.7M) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: Alkermes plc

Revenue for Alkermes plc came in at $496.0M during Jun 2026, a 26.2% improvement versus the preceding quarter. The company recorded net income of $501K, with diluted EPS of $0.00. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this mid-cap Healthcare company. Across the four most recent quarters, ALKS averaged $0.10 in diluted EPS.

ALKS Valuation & Market Position

With a $7.74B market cap, Alkermes plc sits in the mid-cap segment of the market. Analyst price targets span from $54.00 to $65.00, with a consensus of $60.60. At the current price of $46.11, that implies approximately 31% upside potential. Relative to its peer group, ALKS's quantitative score of 67/100 is roughly in line with the peer average of 66/100.

Return on equity for Alkermes plc stands at 8.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.6%, showing how much profit it generates from its asset base. ALKS trades at a trailing price-to-earnings ratio of 114.42, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 3.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.27 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.2%, the inverse of the P/E and a quick read on earnings relative to price.

Alkermes plc's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.25 places it in the grey zone, a middle ground that warrants monitoring.

Alkermes plc has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 336.9% above estimates on average.

Wall Street analysts project Alkermes plc revenue of about $1.82B for fiscal 2026, with EPS near $-0.48. The estimate reflects 13 contributing analysts.

Company Profile

Alkermes plc operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Dublin, IE. The company is led by CEO Blair Jackson. ALKS has traded publicly since 1991.

ALKS Financials

ALKS Latest News

ALKS Analyst Consensus

ALKS MoonshotScore

What Investors Ask About Alkermes plc (ALKS) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources